Brukinsa (Zanubrutinib) for Lymphoma | MyLymphomaTeam

Connect with others who understand.

sign up log in
About MyLymphomaTeam
Powered By

Brukinsa is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with mantle cell lymphoma who have received at least one prior therapy. Brukinsa is also referred to by its drug name, zanubrutinib.

Brukinsa is used as targeted therapy for lymphoma. Brukinsa is a member of a class of drugs called kinase inhibitors. Brukinsa is believed to work by inhibiting the growth of lymphoma cells.

How do I take it?
Prescribing information states that Brukinsa should be taken twice daily.

Brukinsa comes in the form of a capsule.

Side effects
The FDA-approved label for Brukinsa lists common side effects including decreased white blood cells, decreased platelet count, decreased red blood cells (anemia), rash, diarrhea, upper respiratory infection, bruising, and cough.

Rare but serious side effects listed for Brukinsa include low blood cell counts, bleeding problems, other cancers, and heart rhythm problems.

For more details about this treatment, visit:

Brukinsa — BeiGene

Brukinsa — RxList

Continue with Facebook
Continue with Google
Your privacy is our priority. By continuing, you accept our Terms of Use and Privacy Policy.
Already a Member? Log in